MRVI Maravai LifeSciences Holdings

Congressman Scott Peters Tours Maravai’s RNA manufacturing facility

Congressman Scott Peters Tours Maravai’s RNA manufacturing facility

Congressman Peters (D-CA-50) tours Wateridge manufacturing site in San Diego and celebrates Maravai’s impact in COVID vaccine production

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, recently hosted Congressman Scott Peters for a tour of the RNA manufacturing facility at Wateridge Circle in San Diego.

“We were honored to host Congressman Peters at our facility in San Diego,” said Carl Hull, Executive Chairman and Interim CEO of Maravai. “The active engagement of influential government officials such as Scott underscores a commitment to fostering innovation and growth in the life sciences community, in which Maravai is proud to play a leading role.”

Congressman Peters visited the Maravai Wateridge facility on the morning of June 2, and met with Carl Hull, Executive Chairman of the Board and Interim CEO of Maravai, and other members of the senior leadership team before touring the laboratories and conducting a question-and-answer session with Maravai employees. The focus of the visit was to highlight investment in research and development, promoting healthcare innovation, and to celebrate Maravai’s role in COVID vaccine production through the development of its proprietary CleanCap® mRNA capping technology and the future critical role that Maravai will play in U.S.-based pandemic preparedness.

“One of the most important aspects of my job serving California’s 50th district is engaging leading sectors I represent, including the life sciences and biotech fields,” said Rep. Peters. “I enjoyed speaking with Maravai leaders and employees recently who shared details on their work and research related to COVID-19 vaccine production. I thank them for their time and efforts to foster innovation in our community.”

Congressman Peters represents California’s 50th Congressional District, covering the cities of Coronado, San Marcos, Escondido and coastal San Diego. He was elected in 2012, and currently serves on the House Energy and Commerce Committee, the House Budget Committee and the House Equality Caucus. He previously served on the Energy & Commerce Committee and the Veteran’s Affairs Committee, and the House Committee on Science, Space, and Technology. As a former environmental attorney and Chairman of the Port of San Diego, Scott focuses on advancing practical and critical climate policies, and promoting and expanding San Diego’s innovation ecosystem.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies.



Contact Information:
Media Contact: Sara Michelmore
MacDougall Advisors
 
  

Investor Contact: Deb Hart
Maravai LifeSciences
 7
 
EN
06/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE

Maravai Lifesciences Reports First Quarter 2025 Financial Results

Maravai Lifesciences Reports First Quarter 2025 Financial Results SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full y...

 PRESS RELEASE

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 1...

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025 SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference I...

 PRESS RELEASE

Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financi...

Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results Schedules Conference Call for Thursday, March 20, 2025 SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities...

 PRESS RELEASE

Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 E...

Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its ...

 PRESS RELEASE

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue Announces Earnings Release Date SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) --  (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company also announced that it plans to announce its fourth quarter a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch